Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
To learn if giving nivolumab in combination with relatlimab can help to control melanoma that has spread to the brain (melanoma with brain metastases). The safety and side effects of the study drug combination will also be studied.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Spodziewana długość życia dłuższa niż 12 tygodni
- •Potwierdzony rozpoznaniem czerniak złośliwy z przerzutami w mózgu (widoczne na badaniach obrazowych, co najmniej 0,5 cm)
- •Co najmniej jedna zmiana w mózgu niewyleczona wcześniej innym sposobem (niepromieniana)
- •Pobranie próbki guza do badania laboratoryjnego (może być stara próbka z archiwum lub nowa biopsja)
- •Gotowość do regulaminu badania, wizyt u lekarza i badań laboratoryjnych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
M D Anderson Cancer Center
Houston, United States
Trial contact
Hussein Tawbi, MD,PHD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.